The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer

Cancer

Volumn 118, Issue 1, 2012, Pages 157-163

  Rades, Dirk ^a   Setter, Cornelia ^a   Dahl, Olav ^b,c   Schild, Steven E ^d   Noack, Frank ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d MAYO CLINIC   (United States)

Author keywords

androgen receptor; estrogen receptor ; non small cell lung cancer; progesterone receptor; radiotherapy

Indexed keywords

ANDROGEN RECEPTOR; CISPLATIN; ESTROGEN RECEPTOR ALPHA; HEMOGLOBIN; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENDER; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHOTON THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOKING; TREATMENT OUTCOME; TUMOR CELL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 83855165808     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26282     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ,. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66. (Pubitemid 46148091)
2. Olivo-Marston SE, Mechanic LE, Mollerup S, et al. Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis. 2010; 31: 1778-1786.
3. Navaratnam S, Murphy L, Qing G, et al. Estrogen receptor-beta (ER-beta) expression and non-small cell lung cancer (NSCLC) outcome [abstract]. J Clin Oncol. 2010; 28 (suppl): Page. Abstract e21092.
4. Yan M, Chen X, Wang S, Li Y,. Expression of ER and AR in lung cancer [in Chinese]. Zhongguo Fei Ai Za Zhi. 2008; 11: 126-129.
5. Chlebowski RT,. Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol. 2009; 36: 566-571.
6. Barendsen GW,. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982; 8: 1981-1997. (Pubitemid 13167385)
7. Joiner MC, Van der Kogel AJ,. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In:, Steel GG, ed. Basic Clinical Radiobiology. 2nd ed. New York: Oxford University Press; 1997: 106-112.
8. Vaupel P, Thews O, Mayer A, Hockel S, Hockel M,. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol. 2002; 178: 727-731. (Pubitemid 35470269)
9. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
10. Caglayan B, Fidan A, Salepci B, et al. Effects of prognostic factors and treatment on survival in advanced non-small cell lung cancer. Tuberk Toraks. 2004; 52: 323-332.
11. Hsu HC, Wang CJ, Huang EY, Sun LM,. Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factors. Br J Radiol. 2004; 77: 43-48.
12. Jaen Olasolo J, Alonso Redondo E, Leon Jiminez A, Rueda Ramos A,. Non-small lung cancer. Survival after radiotherapy and prognostic factors [in Spanish]. Arch Bronconeumol. 2003; 39: 81-86. (Pubitemid 37074833)
13. Jeremic B, Milicic B, Dagovic A, Acimovic L, Milisavljevic S,. Pretreatment prognostic factors in patients with early-stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy alone. Int J Radiat Oncol Biol Phys. 2006; 65: 1112-1119.
14. Jeremic B, Milicic B, Acimovic L, Milisavljevic S,. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study. J Clin Oncol. 2005; 23: 6873-6880.
15. Jeremic B, Casas F, Wang L, Perin B,. Radiation therapy for early stage (I/II) non-small cell lung cancer. Front Radiat Ther Oncol. 2010; 42: 87-93.
16. Hoyer M,. Improved accuracy and outcome in radiotherapy of lung cancer. Radiother Oncol. 2008; 87: 1-2.
17. Munstedt K, Volzing M, Von Georgi R,. Hemoglobin levels during radiation therapy and their influence on local control and survival of patients with endometrial carcinoma. Oncol Rep. 2004; 11: 711-717.
18. Rades D, Lang S, Schild SE, Alberti W,. Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. Clin Oncol (R Coll Radiol). 2006; 18: 139-144. (Pubitemid 43169143)
19. Becker A, Stadler P, Lavey RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2000; 46: 459-466. (Pubitemid 30067797)
20. Rudat V, Stadler P, Becker A, et al. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol. 2001; 177: 462-468. (Pubitemid 32861426)
21. Rudat V, Vanselow B, Wollensack P, et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol. 2000; 57: 31-37.